As expected, MCF7 xenografts showed lower tumor accumulation compared to BT474 xenografts for both HER2-targeted immunoconjugates (3.06-fold for trastuzumab-IRDye800 and 3.81-fold for pertuzumab-IRDye800) Figure 4(f). Here, ERBB2 is linked to neoplasm.